Growth hormone response in low-dose apomorphine test correlates with nigrostriatal dopamine transporter binding in patients with Parkinson's disease.

Author: BaierP C, HappeS, HelmschmiedK, KochW, MellerJ, PaulusW, TatschK, TingsT, TrenkwalderC, WelschJ, WuttkeW

Paper Details 
Original Abstract of the Article :
Challenge with low-dose apomorphine causes a rise in growth hormone (GH) in patients with Parkinson's disease (PD). We studied 18 patients with early PD, who showed an increase of GH in the low-dose apomorphine test, by means of [(123)I] FP-CIT-SPECT. The mean specific dopamine transporter binding o...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1007/s00702-006-0611-6

データ提供:米国国立医学図書館(NLM)

Parkinson's Disease: A Desert of Degeneration

This research delves into the intricate world of Parkinson's disease, a neurodegenerative disorder that affects movement and coordination. The researchers embarked on a journey to explore the relationship between dopamine transporter binding, a marker of nerve cell degeneration, and the growth hormone response to low-dose apomorphine, a medication commonly used to treat Parkinson's. It was like charting a course through a desert landscape, seeking to understand the progression of this challenging condition.

Mapping the Desert

The study found a significant negative correlation between the increase in growth hormone after apomorphine administration and the amount of dopamine transporter binding in the brain. This discovery was like finding a trail marker in the desert, providing valuable insights into the extent of neurodegeneration. It suggests that low-dose apomorphine challenge could potentially serve as an indirect tool to measure the severity of Parkinson's disease in its early stages.

Navigating the Sands of Parkinson's

This research offers a valuable tool for understanding and managing Parkinson's disease. By understanding the relationship between dopamine transporter binding and growth hormone response, researchers can potentially gain a better understanding of disease progression and develop more effective treatment strategies. The study emphasizes the importance of continuous research to navigate the complex desert of neurodegenerative disorders.

Dr. Camel's Conclusion

This study demonstrates the potential use of low-dose apomorphine challenge as an indirect tool to measure the severity of Parkinson's disease in its early stages. The correlation between growth hormone response and dopamine transporter binding provides valuable insights into the progression of neurodegeneration, offering potential for improved disease management and therapeutic strategies.
Date :
  1. Date Completed 2007-10-09
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

17187291

DOI: Digital Object Identifier

10.1007/s00702-006-0611-6

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.